Kimmtrak (Tebentafusp)

Tebentafusp is a bispecific T‑cell engager that links a soluble T‑cell receptor specific for the gp100 peptide/HLA‑A*02:01 complex on melanoma cells to an anti‑CD3 fragment on T cells. This connection activates T cells, leading to cytokine release and targeted killing of the tumor cells.

The dosing regimen for Kimmtrak is determined by the prescribing oncologist based on the patient’s clinical condition, body weight, and HLA status. The prescriber sets the dose and infusion schedule according to the approved labeling and individual patient factors.

Safety data for Kimmtrak in pregnancy or while breastfeeding are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To order Kimmtrak, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Kimmtrak differs from conventional checkpoint inhibitors by directly redirecting T cells to gp100‑expressing melanoma cells through a bispecific engager. This mechanism can provide clinical benefit in HLA‑A*02:01‑positive uveal melanoma, a disease where many checkpoint inhibitors have limited efficacy.

Kimmtrak must be stored at 2‑8 °C in a refrigerator, protected from light. The product should not be frozen or shaken, and it should be kept in its original packaging until ready for preparation and infusion.

Kimmtrak is given as an intravenous infusion in a clinical setting. The infusion is performed by qualified healthcare personnel, with monitoring for infusion‑related reactions and cytokine release syndrome during and after the administration.

Serious risks include severe cytokine release syndrome, cardiac events such as arrhythmias or myocardial infarction, and rare neurotoxic effects. Patients should be closely monitored for these events, and appropriate supportive care should be available.

Kimmtrak should not be used in patients who lack the HLA‑A*02:01 allele, as the drug requires this specific HLA presentation to target melanoma cells. It is also contraindicated in patients with active uncontrolled infections or those receiving live vaccines.